PYC Prepares for Upcoming Safety, Efficacy Read-Outs Across All Drug Development Programs; Shares Up 3%
MT Newswires Live
Oct 27
PYC Therapeutics (ASX:PYC) said it is preparing for upcoming human safety and efficacy read-outs across its polycystic kidney disease (PKD), lead blinding eye disease (RP11), second blinding eye disease (ADOA), and neurodevelopmental disorder (PMS) drug development programs, according to a Monday filing with the Australian bourse.
Data for RP11 is expected in the fiscal year, while data for PKD and ADOA is expected the next year, the filing said. Data for PMS is expected in fiscal 2027.
The biotechnology company's shares jumped almost 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.